ClassID:

170402

G01N2333/48 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving growth factors Nerve growth factor [NGF]

Recent Application in this class:
#1
20260049998
2026-02-19

METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS

#2
20250347700
2025-11-13

METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS

#3
20240393350
2024-11-28

METHOD FOR THE EARLY DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF QUANTIFICATION OF PRONGF AND DERIVED FORMS THEREOF

#4
20240018481
2024-01-18

RECOMBINANT CHO CELL, CONSTRUCTION METHOD THEREFOR, AND DETECTION SYSTEM AND METHOD USING SAME

#5
20230151085
2023-05-18

ANTI-HUMAN NERVE GROWTH FACTOR ANTIBODY

#6
20200225233
2020-07-16

Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD

#7
20180100153
2018-04-12

Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in VGF expressing cancers

#8
20160334422
2016-11-17

Biomarker and methods for early diagnosis of Alzheimer's disease

#9
20160304596
2016-10-20

HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS

#10
20160266120
2016-09-15

Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD

#11
20160138023
2016-05-19

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

#12
20150209312
2015-07-30

Modulation sAPP, sAAPα and BDNF levels in individuals diagnosed with FXS and ASD

#13
20150105289
2015-04-16

BIOMARKERS FOR LOWER URINARY TRACT SYMPTOMS (LUTS)

#14
20150017095
2015-01-15

PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

#15
20130171173
2013-07-04

Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

#16
20110319475
2011-12-29

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

#17
20110294690
2011-12-01

DIFFERENTIAL DIAGNOSTIC BIOMARKERS OF STROKE MIMICKING CONDITIONS AND METHODS OF USE THEREOF

#18
20110293636
2011-12-01

Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf

#19
20110229485
2011-09-22

INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA

#20
20110091476
2011-04-21

Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors

#21
20110040076
2011-02-17

Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors

#22
20100310568
2010-12-09

Ninjurin-1 modulation and uses thereof

#23
20100074900
2010-03-25

Prostaglandin E2 dual variable domain immunoglobulins and uses thereof

#24
20090155274
2009-06-18

Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors

#25
20090068200
2009-03-12

Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

#26
20080033157
2008-02-07

Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors

#27
20070123945
2007-05-31

Methods for the prediction of arrhythmias and prevention of sudden cardiac death

#28
20060147932
2006-07-06

Methods of screening for modulators of nerve growth factor

#29
20060051818
2006-03-09

Method for NGF assay for in vitro diagnosis of breast cancer and therapeutic use

#30
20050233955
2005-10-20

Stimulation of nerve cell regeneration

#31
20050130233
2005-06-16

Methods of diagnosing or treating Alzheimer's disease on basis of increased cerebrospinal fluid levels of nerve growth factor

#32
20050074821
2005-04-07

Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors